Local and regional immunotherapy of cancer with interleukin 2

Selective in Vitro Growth of T Lymphocytes from Normal Human Bone Marrows

1976 • 2,458 citations

Interleukin-2: Inception, Impact, and Implications

1988 • 2,166 citations

The fate of interleukin-2 after in vivo administration.

1983 • 358 citations

Immunotherapy of cancer using interleukin 2: current status and future prospects

1988 • 256 citations

Three-Dimensional Structure of Interleukin-2

1987 • 242 citations

Lymphokine-activated killer cell activity

1987 • 235 citations

Tumour regression after intralesional injection of interleukin 2 (IL‐2) in bladder cancer. Preliminary report

1984 • 170 citations

Treatment of recurrent squamous cell carcinoma of the head and neck with low doses of lnterleukin-2 injected periiymphatically

1988 • 151 citations

The anti-tumor efficacy of lymphokine-activated killer cells and recombinant interleukin 2 in vivo: direct correlation between reduction of established metastases and cytolytic activity of lymphokine-activated killer cells.

1986 • 110 citations

Lymphokine-activated tumor inhibition in vivo. I. The local administration of interleukin 2 triggers nonreactive lymphocytes from tumor-bearing mice to inhibit tumor growth.

1985 • 110 citations

Induction of lymphokine-activated killer cells by intrapleural instillations of recombinant interleukin-2 in patients with malignant pleurisy due to lung cancer.

1987 • 100 citations

Local administration of autologous lymphokine-activated killer cells and recombinant interleukin 2 to patients with malignant brain tumors.

1988 • 98 citations

Local administration of cells containing an inserted IL-2 gene and producing IL-2 inhibits growth of human tumours in nu/nu mice

1988 • 79 citations

Local and systemic effects during interleukin-2 therapy of mouse mammary tumors.

1987 • 60 citations

Growth inhibition of a MC-induced mouse sarcoma by TCGF (IL 2)-containing preparations

1983 • 59 citations

Tumor Immunotherapy by Local Injection of Interleukin 2 and Non-Reactive Lymphocytes

2015 • 34 citations

Tumour inhibitory effects of TCGF/IL-2/-containing preparations

1985 • 33 citations

Local interleukin 2 therapy of mouse mammary tumors of various immunogenicities.

1988 • 32 citations

Intralesional injection of interleukin-2-expanded autologous lymphocytes in melanoma and breast cancer patients: a pilot study.

1984 • 31 citations

Successful immunotherapy of mouse melanoma and sarcoma with recombinant interleukin-2 and cyclophosphamide.

1986 • 29 citations

The anti-tumour efficacy of human recombinant interleukin 2

1987 • 26 citations

Administration of slowly released recombinant interleukin 2 Augmentation of the efficacy of adoptive immunotherapy with lymphokine-activated killer (LAK) cells

1986 • 25 citations

Effect of recombinant interleukin 2 (R-IL2) on in vivo growth of murine myeloma X5563

1986 • 24 citations

Influence of the administration schedule on the therapeutic effect of interleukin‐2

1987 • 22 citations

Defect in lectin-induced interleukin 2 production by peripheral blood lymphocytes of patients with invasive urinary bladder carcinoma

1988 • 21 citations

Cancer immunotherapy using local interleukin 2 administration

1987 • 21 citations

Local immunotherapy of cancer with interleukin 2

1989 • 16 citations

Lymphokine-activated killer (LAK) cells: I. Age-dependent decline of LAK cell-mediated cytotoxicity

1987 • 16 citations

Local treatment with human recombinant interleukin 2 inhibits growth of MC-induced sarcomas in syngeneic mice.

1986 • 10 citations

Recombinant interleukin-2 inhibits growth of human tumor xenografts in congenitally athymic mice

1987 • 9 citations

Activation of killer cells from blood of urinary bladder carcinoma patients by short-term treatment with recombinant interleukin 2.

1986 • 8 citations

Generation of LAK cells depends on the age of LAK cell precursor donors.

1988 • 5 citations

Chemoimmunotherapy of MC-induced mouse sarcomas with human recombinant interleukin 2 and cyclophosphamide: age-dependent decline of the therapeutic efficacy.

1989 • 4 citations

Expression of IL-2 receptors on peripheral blood lymphocytes from young adult and aged human donors.

1987 • 2 citations